Selank

PRODUCT CLASSIFICATION Anxiolytic Peptide
ACNE-FREE No
WATER RETENTION-FREE No
HBR-FREE No
HEPATOTOXICITY-FREE No
AROMATIZATION-FREE No
MANUFACTURER Deus Medical
LAB TESTING Refer to Document
WAREHOUSE LOCATION EU Warehouse 2
ACTIVE SUBSTANCE Selank Anxiolytic Peptide

In the ever-evolving field of biotechnology, groundbreaking biologically active substances, including "cognitive enhancers" or "nootropics," are emerging. Among these is Selank, previously known as ?TP-7,? a synthetic peptide designed to enhance mental well-being.

Promoted as an effective "anti-anxiety" agent, Selank is also believed to support learning and improve energy levels, all without the worry of negative side effects or addiction. Developed by the Institute of Molecular Genetics (Russian Academy of Sciences) in collaboration with the V.V. Zakusov Research Institute of Pharmacology, Selank is a smaller synthetic protein compared to most natural peptides, alongside its counterpart, Semax.

Selank is crafted by combining the sequence of tuftsin, a naturally occurring peptide found in the antibody IgG, with a stabilizing sequence to enhance its molecular robustness. Research indicates that both tuftsin and Selank may reduce anxiety and elevate serotonin levels in animal models, with Selank demonstrating slightly superior effectiveness.

In Russia, Selank is approved for managing generalized anxiety disorder (GAD) and is recognized as a nootropic, although it remains unapproved by the FDA for any medical conditions. Despite this, Selank is widely accessible in various regions, often marketed as a "nutritional supplement."

While the exact workings of Selank are not fully elucidated, it is believed to stabilize enkephalins in the bloodstream?natural peptides that may play a role in moderating the body's stress response. Some studies have suggested interactions between Selank and GABA receptors, which are linked to calming effects. One mouse study indicated that Selank treatment led to increased activity in inhibitory GABA-reliant neurons, resulting in reduced brain activity, similar to sedation.

Moreover, preliminary research has observed increases in BDNF, a crucial neurotrophic factor that supports learning and memory, which may contribute to Selank's cognitive benefits. Additionally, Selank appears to modulate levels of neurotransmitters like norepinephrine, dopamine, and serotonin, all essential for motivation, focus, and pleasure.

However, findings from various studies remain inconsistent; one animal study observed that Selank raised norepinephrine levels while lowering dopamine and serotonin, while another suggested increases in norepinephrine and dopamine without affecting serotonin. Thus, the precise effects and mechanisms of Selank warrant further investigation.

A preliminary clinical trial involving 62 participants indicated that Selank administration resulted in reduced anxiety symptoms, particularly among those with pre-existing anxiety disorders. In another study with 60 patients suffering from anxiety and phobias, similar benefits were noted, persisting for up to a week following the last dose. Additionally, research involving 70 anxiety patients revealed that Selank could enhance the effects of phenazepam (an anti-anxiety medication prohibited in some U.S. states) while mitigating negative side effects like drowsiness and memory impairment. Animal studies have also demonstrated Selank's capacity to alleviate anxiety in mice, especially those with higher anxiety levels.

Though evidence is limited, these findings suggest that Selank may be beneficial in alleviating anxiety. However, further research is essential to validate its efficacy and safety in humans. If you're grappling with anxiety, consult your healthcare provider to explore whether Selank could be a suitable option for you, always following your doctor's guidance instead of relying solely on supplements.

Selank has been shown to stabilize memory traces (potentially enhancing memory retention) in rats during a 30-day trial, although the methods for assessing memory remain ambiguous. Additionally, one animal study indicated that Selank could assist in preserving memory in monkeys. More human studies are necessary to determine the effects of Selank on healthy individuals, and its safety is yet to be confirmed, implying a need for caution until more research is available.

In one study, rats with toxin-induced brain damage treated with Selank reportedly returned to normal brain activity levels.

Selank has demonstrated the ability to reduce depressive symptoms (as measured by immobility during forced swimming tests) in mice, with lower doses proving more effective than higher doses.

Preliminary animal research suggested that Selank injections raised antioxidant levels in the livers of stressed mice.

In an intriguing study involving sedated cats, Selank was found to reduce blood pressure by approximately 30% for up to three minutes while enhancing cerebral blood flow by about 24% for up to ten minutes. While these findings are captivating, their short duration raises questions regarding clinical significance, especially as these outcomes are based solely on animal studies.

Given that anxiety is a common symptom of alcohol withdrawal, one study indicated that rats consuming a 10% ethanol solution for 24 weeks experienced decreased anxiety when treated with Selank following a 48-hour withdrawal period.

An animal study found that rats on a high-fat diet experienced 35% less weight gain with Selank treatment, along with more than a 58% drop in total cholesterol levels and a 23.5% decrease in blood glucose levels.

In research involving mice with breast cancer, those treated with Selank exhibited slower tumor growth and longer lifespans compared to untreated counterparts. However, these early results do not imply that Selank is a viable cancer treatment; further investigation is necessary to validate such findings, and it should never replace conventional cancer therapies.

After Selank treatment, the spleens of mice displayed elevated levels of several inflammatory response genes, indicating potential protective effects against inflammation.

Moreover, Selank has shown promise in reducing stomach ulcer size in animal models, likely due to enhanced lymph flow?an integral part of the immune system?towards the stomach. However, extensive human research is needed to confirm these effects and their underlying mechanisms.

Selank has been associated with increased IL-6 levels in blood cells from depressed patients, with IL-6 being an inflammatory protein vital for infection defense. Nonetheless, one cell-based study suggested Selank might stimulate the release of interferons, yet an animal study showed no antiviral benefits from Selank treatment, raising questions about its applicability in this area.